Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Immuno-oncology (IO) is a class of treatment modality designed to augment the body’s natural immune defense against cancer. The IO space is currently dominated by therapeutics development programs targeting immune checkpoint modulators and cytokines as these molecules hold significant promise in cancer therapy. Another key modality is the modulation of Fc-mediated effector mechanisms of therapeutic antibodies, including ADCC, ADCP, CAR-T, CAR-NK, CDC, and other cytotoxicity-focused applications.
Eurofins DiscoverX® offers the most comprehensive product portfolio of cell lines, cell pools, eXpress™ assay kits, and bioassay kits to enable fast, effective, and clinically relevant understanding of IO targets, their pathways, and mechanisms to empower quicker development of IO therapeutics. Continuous culture cell lines allow for full-scale interrogation, screening, and profiling of IO therapeutic MOAs (mechanism of actions), while the ready-to-use qualified bioassays are developed to meet the industry requirements and regulatory expectations. Eurofins DiscoverX offers fast and seamless implementation for IO therapeutic MOA confirmation, stability studies, and potency testing in QC lot release programs as a thaw-and-assay platform.
Learn how you can rapidly screen and develop small molecules, biologics (peptides, antibodies, or bispecific antibodies), or cellular therapies for your IO drug discovery and development program.
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Fast-track your IO drug discovery and development with physiologically relevant cell-based assays. Eurofins DiscoverX offers the most comprehensive portfolio of cell-based assays to enable fast, effective, and clinically relevant understanding of IO to interrogate targets, pathways, and mechanisms to empower quicker development of IO therapeutics.